for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Innoviva Inc

INVA.OQ

Latest Trade

10.97USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.76

 - 

20.53

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.97
Open
--
Volume
--
3M AVG Volume
12.89
Today's High
--
Today's Low
--
52 Week High
20.53
52 Week Low
10.76
Shares Out (MIL)
101.28
Market Cap (MIL)
1,153.58
Forward P/E
7.67
Dividend (Yield %)
--

Next Event

Q3 2019 Innoviva Inc Earnings Release

Latest Developments

More

Innoviva Reports Q2 EPS Of $0.34

Innoviva Says Q1 Revenue Rose 5 Percent To $55.2 Million

Sarissa Capital Management Reports 5.73 Pct Stake In Innoviva As Of Feb 14

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Innoviva Inc

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Industry

Biotechnology & Drugs

Contact Info

2000 Sierra Point Pkwy Ste 500

+1.650.2389600

http://www.inva.com/

Executive Leadership

Geoffrey L. Hulme

Interim Principal Executive Officer

Marianne Y. Zhen

Chief Accounting Officer

George W. Bickerstaff

Independent Director

Mark A. DiPaolo

Independent Director

Jules A. Haimovitz

Independent Director

Key Stats

3.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.3K

2019(E)

0.2K
EPS (USD)

2016

0.530

2017

1.170

2018

1.750

2019(E)

1.485
Price To Earnings (TTM)
3.38
Price To Sales (TTM)
4.42
Price To Book (MRQ)
5.09
Price To Cash Flow (TTM)
2.75
Total Debt To Equity (MRQ)
170.58
LT Debt To Equity (MRQ)
170.58
Return on Investment (TTM)
85.84
Return on Equity (TTM)
82.66

Latest News

BRIEF-Innoviva Reports Q1 Adjusted Earnings Per Share $0.35

* Q1 EARNINGS PER SHARE VIEW $0.53 -- THOMSON REUTERS I/B/E/S

BRIEF-Sarissa Capital Reconstitutes Innoviva Board

* JULES HAIMOVITZ, SARAH SCHLESINGER, AND MARK DIPAOLO WILL BE ADDED TO INNOVIVA BOARD Source text for Eikon:

BRIEF-Innoviva Enteres Into Agreement With Sarissa Capital Management

* INNOVIVA INC - ENTERED INTO AN AGREEMENT WITH SARISSA CAPITAL MANAGEMENT LP, AND CERTAIN OF ITS AFFILIATES

Drug company Innoviva settles with activist hedge fund Sarissa: sources

U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

BRIEF-Innoviva Reports Q4 Adj Earnings Per Share $0.55

* INNOVIVA REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Innoviva Appoints Eric D'Esparbes As Co's Interim Principal Executive Officer

* INNOVIVA SAYS ON FEB 7, CO ANNOUNCED APPOINTMENT OF ERIC D'ESPARBES AS CO'S INTERIM PRINCIPAL EXECUTIVE OFFICER, EFFECTIVE FEB 6 - SEC FILING

BRIEF-GSK and Innoviva announce positive data from COPD study

* GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Innoviva reports Q3 adj earnings $0.31/shr

* Innoviva reports third quarter 2017 financial results and provides business updates

BRIEF-GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD

* CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED COPD EXACERBATIONS

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

GlaxoSmithKline Plc <GSK.L> and Innoviva Inc <INVA.O> said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

BRIEF-Innoviva prices offering of $175 mln of 2.50 pct convertible senior notes

* Innoviva Inc. prices offering of $175 million of 2.50 pct convertible senior notes Source text for Eikon: Further company coverage:

BRIEF-Innoviva proposes $175 mln offering of convertible senior notes

* Innoviva announces proposed offering of $175 million of convertible senior notes

BRIEF-Innoviva Q2 adjusted earnings per share $0.35

* Innoviva reports strong second quarter 2017 financial results

UPDATE 1-Innoviva director vote drama hands last-minute loss to Sarissa

Shareholders of Innoviva Inc. handed a narrow victory to the U.S. respiratory drug company, according to a person close to the matter, as its fight against activist hedge fund Sarissa Capital saw several last minute twists and turns.

Innoviva prevails in proxy fight against activist Sarissa-source

Shareholders of Innoviva Inc. handed a narrow victory to the U.S. respiratory drug company, voting in its three directors after fending off nominees from activist hedge fund Sarissa Capital, according to a source close to the matter.

Activist Sarissa says Innoviva backed out of proxy settlement deal

Activist hedge fund Sarissa Capital Management LP said on Wednesday that U.S. respiratory drug company Innoviva Inc <INVA.O> reneged on a proxy settlement deal that was struck earlier in the day.

BRIEF-Sarissa Capital Management says Innoviva accepted offer to settle proxy contest

* Sarissa Capital Management - Innoviva accepted an offer from Sarissa Capital to settle proxy contest by adding two Sarissa nominees to the board Source text for Eikon: Further company coverage:

BRIEF-Innoviva issues statement on upcoming annual meeting of stockholders

* Innoviva issues statement on upcoming annual meeting of stockholders Source text for Eikon: Further company coverage:

BRIEF-Sarissa Capital issues statement regarding its nomination of a minority slate to the board of Innoviva

* Sarissa Capital issues statement regarding its nomination of a minority slate to board of directors of Innoviva Source text for Eikon: Further company coverage:

Innoviva to review costs, executive pay following Sarissa pressure

Drug company Innoviva Inc said on Thursday it would undertake a review of its costs, including executive compensation following pressure from activist investor Sarissa Capital Management LP.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up